Companies: 10,795·Total market cap: $144.5T
Monopar Therapeutics Inc.

Monopar Therapeutics Inc.

MNPRNASDAQHealthcare● Active
$60.61
+$1.13(+1.90%)
Market Cap$406030027
P/E Ratio—
52W High$105
52W Low$29.18
Shares OutstandingFinancialsRevenue

Monopar Therapeutics Inc. (MNPR) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

MNPR · shares outstanding · updated Jun 9, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
7.4M▼ -35.24% YoY Change
FY · as of Dec 31, 2025 · Reported in USD
vs 11.4M in FY 2024
Diluted Shares Outstanding
7.4M
incl. options, RSUs, convertibles
Dilution Spread
+0.00%
Diluted vs Basic
YoY Change
-35.24%
year-over-year
Float (Free Float)
4.1M
publicly tradable shares
61.8% of total
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-09

Shares Outstanding Growth Rate

3-Year CAGRdeclining
-16.5%
2022 → 2025
5-Year CAGRdeclining
-7.5%
2020 → 2025
10-Year CAGRdeclining
-0.9%
2015 → 2025
ⓘ

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2025Latest
Diluted Shares: 7.4M
7.4M
-35.24%
FY 2024
Diluted Shares: 11.5M
11.4M
-21.14%
FY 2023
Diluted Shares: 14.5M
14.5M
+14.10%
FY 2022
Diluted Shares: 12.7M
12.7M
+1.97%
FY 2021
Diluted Shares: 12.5M
12.5M
+13.82%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs MNPR
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+>999%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+>999%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+>999%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+>999%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+>999%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+>999%
#7
Monopar Therapeutics Inc.MNPR
Monopar Therapeutics Inc.YOU
7.4M—

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

Monopar Therapeutics Inc. (MNPR) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2025, Monopar Therapeutics Inc. reports 7.4M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

Monopar Therapeutics Inc.'s basic shares outstanding (7.4M) represents currently issued shares. Diluted shares outstanding (7.4M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.

Shares Outstanding vs. Float (Free Float)

Monopar Therapeutics Inc.'s float is 4.1M (61.8% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float4.1M(61.8%)
Outstanding6.7M

ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · USD

About shares outstanding & methodology

Monopar Therapeutics Inc. (MNPR) shares outstanding history from 2015 to 2025. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

Monopar Therapeutics Inc. shares outstanding for the fiscal year ending December 31, 2025 were 7.4M, a 35.24% decline year-over-year. Monopar Therapeutics Inc. FY 2025 shares outstanding were 7.4M, a -35.24% decline from FY 2024.

Monopar Therapeutics Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of -0.9% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.
Market capSplitsEarningsFinancials (Income)Cash on handFree cash flowNet incomePrice history

Frequently asked questions

MNPR shares outstanding · 4 questions

As of December 31, 2025, Monopar Therapeutics Inc. (MNPR) has approximately 7.4M basic shares outstanding and 7.4M diluted shares outstanding. This represents a -35.24% year-over-year change from FY 2024 (11.4M). Monopar Therapeutics Inc.'s declining share count is primarily driven by its share buyback program. For the complete historical data table, see the history table above.

MNPR shares outstandinghow many shares does MNPR haveMNPR basic shares 2025MNPR diluted shares

▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Monopar Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-09